Silverarc Capital Management »

Prothena shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Prothena (PRTA) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Prothena

Tip: Access up to 7 years of quarterly data

All positions including Prothena held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prothena by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $1.3M 27k 48.25
2023-06-30 $3.4M 50k 68.28
2022-12-31 $4.3M 72k 60.25
2022-09-30 $7.0M 115k 60.63

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Prothena

EcoR1 Capital
T. Rowe Price Associates
Wellington Management Company
Henderson Group
Palo Alto Investors
First Light Asset Management
Vanguard Group
Ikarian Capital
Dimensional Fund Advisors
Boxer Capital
Artal Group
Eventide Asset Management
Maple Rock Capital Partners
Jpmorgan Chase & Co
Goldman Sachs Group

View all funds holding Prothena